Cost-effectiveness of vaccination against HPV of adolescent girls in the regions of Russian Federation

Vaccination against human papillomavirus infection is not included in the National Calendar of Preventive Vaccinations of the Russian Federation, and vaccination is only available through regional programs. At the same time, the cost­effectiveness of vaccination in the regions of the Russian Federation may vary significantly.

The aim of this study was to assess the cost­effectiveness of vaccination with the 4­valent HPV vaccine in 12­year­old girls in the regions of the Russian Federation.

Materials and methods. A Markov model with a lifetime horizon for 12­year­old girls based on epidemiological data for the Russian Federation was used. The cost­effectiveness analysis was carried out from societal perspective. Costs and life expectancy were discounted at 3% per year.

Results. In most regions of the Russian Federation, vaccination of girls is cost saving or highly cost­effective (the cost per additional quality­adjusted life year (QALY) does not exceed the value of gross regional product per capita). Only in Dagestan, Chechnya and Ingushetia the vaccination of girls can be considered as cost­effective, but not highly costeffective tool (incremental costs per QALY exceed the GRP per capita by 14,2­37,0%).

Conclusions. Vaccination of girls before the onset of sexual activity with the 4­valent HPV vaccine is highly costeffective in most regions of the Russian Federation.

1. Malignant neoplasms in Russia in 2022 (morbidity and mortality)/ ed. A.D. Kaprina, V.V. Starinskogo, A.O. Shaxzadovoj. – Moscow; 2023: 275 р.

2. Rudakova A.V., Kharit S.M., Tikhomirova K.K., Lobzin Yu.V. Cost-effectiveness of gender neutral vaccination of adolescents against human papillomavirus infection in the Russian Federation // Zhurnal infektologii.2023; №4: 102-109.

3. Simons JJM, Vida N, Westra TA, Postma M.J. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine. 2020; Vol. 38(30): 4687-4694.

4. Cody P, Tobe K, Abe M, Elbasha EH. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis. 2021; 21(1): P.11.

5. Resolution of the Government of the Russian Federation of 28.12.2023 N 2353 “On the Program of state guarantees for the free provision of medical care to citizens for 2024 and for the planning period of 2025 and 2026”. http://static.government.ru/media/files/vB0TvgWlcYbdAUFJomenUk3B0sjTuLA8.pdf

6. Letter of the Ministry of Health of Russia dated 19.02.2024 N 31-2/200 (as amended on 15.07.2024) “On methodological recommendations on methods of payment for medical care at the expense of compulsory medical insurance funds” (together with the “Methodological recommendations on methods of payment for medical care at the expense of compulsory medical insurance funds”, approved by the Ministry of Health of Russia N 31-2/200, FFOMS N 00-10-26-2-06/2778 on 19.02.2024). https://www.consultant.ru/document/cons_doc_LAW_470284/

7. Federal Law “On the Budget of the Federal Fund for Compulsory Medical Insurance for 2024 and for the Planning Period of 2025 and 2026” dated November 27, 2023 N 541-FL.

8. Omel`yanovskij V.V., Avksent`eva M.V., Sura M.V., Ivaxnenko O.I. Methodological recommendations for calculating costs during clinical and economic research of medicines. – Moscow; 2017: 24.

9. Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papil-lomavirus and Related Diseases in Russian Federation. Summary Report 10 March 2023. [Date Accessed]

10. Anogenital (venereal) warts. Clinical recommendations. 2021. Available from https://cr.minzdrav.gov.ru/recomend/204

11. Sevost`yanova O. Yu., Oboskalova T . A ., Chumarnaya T . V. et al. Epidemiological features of cervical intraepithelial neoplasia incidence in a modern metropolis // Opuxoli zhenskoj reproduktivnoj sistemy`. 2023;T.19(1):112–9.

12. Squamous cell carcinoma of the anal canal, anal margin, perianal skin. Clinical recommendations. 2020. Available from: https://cr.minzdrav.gov.ru/recomend/555

13. Kostin A.A., Starinskij V.V., Samsonov Yu.V., Asratov A.T. Analysis of statistical data on malignant neoplasms associated with the human papillomavirus // Issledovaniya i praktika v medicine. 2016;T. 3.№ 1: 66-78.

14. Qendri V, Bogaards JA, Baussano I, Lazzarato F, Vnsk S, Berkhof J. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health. 2020; Nov;5(11): e592-e603. doi: 10.1016/S2468-2667(20)30209-7.

15. Macroeconomics and health: Investing in health for economic development. Report of the commission on macroeconomics and health to the WHO [Internet]. Geneva; 2001. Available from: http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf